Overview
- Intercept launched with a $500 million pledge led by Stripe and additional support from Anthropic, the OpenAI Foundation, Flu Lab, Bill Gates, and traders at Jane Street, according to Intercept spokespeople.
- The initiative named Nan Ransohoff and Charlie Petty as leaders and has recruited advisers with vaccine and regulatory experience, including Peter Marks and Moncef Slaoui.
- Intercept will use grants and investments to de-risk candidates by funding early-stage clinical work for broad vaccines and prophylactic therapies and to pilot air‑cleaning systems in public spaces and workplaces.
- Scientists behind the plan cite modern tools—RNA drugs, engineered antibodies and computational protein design—as making multi‑virus countermeasures technically plausible, but the common cold is caused by more than 200 viruses which creates major scientific and commercial hurdles.
- The group says the effort will help fill gaps left by flat public research budgets and limited pharma incentives and the campaign could trigger pilots, further private funding, and industry interest if Intercept can advance treatments through Phase I/II trials.